US-based Allurion’s (NYSE: ALUR) weight-loss intragastric balloon has been first applied in Shanghai Ruijin Hospital’s Hainan subsidiary, offering a non-invasive weight loss solution for obese patients with a body mass index (BMI) greater than 27. This innovative device provides an alternative approach to weight management in a hospital setting.
Clinically Proven Weight Loss with Allurion Gastric Balloon
The Allurion gastric balloon is clinically proven to provide long-term, sustainable weight loss results. Physicians place a soft, water-filled balloon in the patient’s stomach, reducing stomach volume and promoting a feeling of fullness. This product stands out as the only one globally that does not require placement through endoscopy, surgery, or anesthesia, offering a more patient-friendly experience. Patients can swallow the balloon under the professional guidance of a doctor, making the process less invasive and more accessible.
How the Allurion Balloon Works
The balloon is initially presented as a drug capsule. After the patient swallows the capsule, a specialized antibacterial stabilizing solution is injected through a catheter connected to the capsule. Once filled, the catheter is gently pulled to separate it from the balloon, and then removed from the body. The entire placement process takes approximately 15-20 minutes. With professional health tracking and a dietary and exercise management plan developed by doctors, patients can achieve their long-term weight loss goals and maintain the results.
Global Recognition and Safety Profile
The Allurion gastric balloon is the first and only weight loss device recommended by the National Institute for Health & Clinical Excellence of the UK (NICE) and has been approved in 50 countries worldwide. Study data indicates that compared to other US Food and Drug Administration (FDA) approved gastric juice balloon products, the Allurion gastric balloon does not require endoscopy and anesthesia, reducing the incidence of adverse events by 93-95%.-Fineline Info & Tech
